Giuseppe Lombardi, Head of the Neuro-Oncology Unit at the Veneto Institute of Oncology, shared a post on LinkedIn about a paper she co-authored with colleagues published in the Journal of Clinical Oncology:
“I am pleased to share the publication of the international STELLAR phase III trial in the JCO Journals, a study in which our center had the privilege to participate.
The trial evaluated the combination of eflornithine + lomustine in patients with recurrent IDH-mutant grade 3 astrocytoma.
Key results:
- PFS doubled with the combination therapy (15.8 vs 7.2 months)
- S significantly improved (34.9 vs 23.5 months)
These findings represent an important step forward for patients with recurrent grade 3 astrocytoma, a setting with very limited therapeutic options.
A sincere thank you to all colleagues involved in the STELLAR study and to the entire Istituto Oncologico Veneto IOV – IRCCS Neuro-Oncology team for their dedication, expertise, and commitment to improving patient care.”
Title: STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma
Authors: Howard Colman, Giuseppe Lombardi, Eric T. Wong, Tobias Walbert, Marica Eoli, Andrew B. Lassman, David M. Peereboom, Sani H. Kizilbash, Carlos Kamiya-Matsuoka, Marshall W. Pitz, Roy E. Strowd, Annick Desjardins, Priya Kumthekar, Warren Mason, Alessia Pellerino, Riccardo Soffietti, Nicholas Butowski, Peter A. Forsyth, Mohamed A. Hamza, Peter Hau, Enrico Lallana, Burt Nabors, David Piccioni, Erik J. Uhlmann, Liam C. Welsh, Patrick Y. Wen, Jorg Dietrich, Chao Wang, Victor A. Levin
Read the Full Article in the Journal of Clinical Oncology:
More posts featuring Giuseppe Lombardi.